{"id":"arct-154","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"target":"SARS-CoV-2 spike protein","explanation":"ARCT-154 utilizes self-amplifying RNA (saRNA) technology that encodes both the SARS-CoV-2 spike protein antigen and viral replication machinery. Once delivered into cells, the saRNA replicates itself to produce higher levels of the spike protein antigen, potentially enabling lower vaccine doses while generating robust immune responses.","oneSentence":"Self-amplifying mRNA vaccine encoding SARS-CoV-2 spike protein that replicates within cells to produce sustained antigen expression."},"_scrapedAt":"2026-03-28T04:54:17.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123606,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tozinameran","brand":"Comirnaty","company":"BioNTech/Pfizer","rationale":"mRNA COVID-19 vaccine"},{"name":"elasomeran","brand":"Spikevax","company":"Moderna","rationale":"mRNA COVID-19 vaccine"},{"name":"ARCT-2304","brand":null,"company":"Arcturus Therapeutics","rationale":"Next-generation saRNA COVID-19 vaccine from same company"}],"description":"ARCT-154 is an investigational self-amplifying mRNA vaccine developed by Arcturus Therapeutics for COVID-19. It uses the company's STARR self-replicating RNA technology platform to potentially enable lower doses and enhanced immune responses compared to conventional mRNA vaccines.","indications":{"approved":[{"status":"investigational","condition":"COVID-19","patientPopulation":"Adult population for primary vaccination and booster"}]},"trialDetails":[{"nctId":"NCT05012943","phase":"PHASE2, PHASE3","title":"The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)","status":"COMPLETED","sponsor":"Vinbiocare Biotechnology Joint Stock Company","startDate":"2021-08-15","conditions":"COVID-19 Vaccines","enrollment":19474},{"nctId":"NCT05037097","phase":"PHASE1, PHASE2","title":"A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-08-30","conditions":"COVID-19, SARS-CoV-2 Infection, Corona Virus Infection","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARCT-154","genericName":"ARCT-154","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}